The availability of novel therapies for the treatment of multiple myeloma has had a dramatic impact on the depth of response that can be expected on initial treatment. Despite these advances, disease relapse remains inevitable in most patients and brings with it a different set of priorities for therapy. The most recent wave of novel agents may have a particular impact in the relapsed setting. In this review, we examine the evidence currently available from clinical trials for the use of novel agents, particularly in the formation of triplet therapy. We consider data supporting the addition of the proteasome inhibitors carfilzomib and ixazomib, or the monoclonal antibodies elotuzumab or daratumumab, to a treatment backbone of lenalidomide and dexamethasone. The clinical data set is less well developed for the addition of a third agent to the combination of bortezomib and dexamethasone; nonetheless, data are presented supporting the addition of the histone deacetylase inhibitor panobinostat, or elotuzumab or daratumumab. While acknowledging the lack of head-to-head data on which to base comparisons between the numerous regimens, we collate the latest data in order to provide a basis on which to make clinical decisions in this rapidly advancing field.
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The treatment of patients with multiple myeloma (MM) has changed dramatically over the past two decades with the introduction of novel agents, such as the proteasome inhibitor bortezomib and the immunomodulatory drugs thalidomide, lenalidomide and pomalidomide . The evolution of the MM treatment landscape is continuing (Fig 1) , with phase 3 data supporting the approval of the next-generation proteasome inhibitor carfilzomib, the histone deacetylase inhibitor panobinostat, the monoclonal antibodies elotuzumab and daratumumab, and the orally bioavailable proteasome inhibitor ixazomib (Table I) [http://www.ema.eu ropa.eu/docs/en_GB/document_library/EPAR_-_Product_Inf ormation/human/003790/WC500197692.pdf; http://www.e ma.europa.eu/docs/en_GB/document_library/EPAR_-_Produc t_Information/human/003967/WC500206673.pdf; http:// www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002682/WC500147717.pdf; http:// www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004077/WC500207296.pdf;(All accessed 22 July 2016); http://www.ema.europa.eu/docs/en_ GB/document_library/EPAR_-_Product_Information/human/ 003844/WC500217620.pdf, accessed 21 February 2016]. Furthermore, recent data indicate that some of these emerging therapies are also potentially useful in the treatment of patients who are ineligible for autologous stem cell transplantation (Raza et al, 2017) .
It has become apparent that successful long-term outcomes are dependent on achieving the maximal response to initial therapy . Consequently, much of the attention surrounding the first wave of new treatment agents -such as thalidomide, bortezomib and lenalidomide -has focused on how best to integrate them into induction regimens to maximise the effectiveness of autologous stem cell transplantation as an initial therapeutic strategy (Harousseau, 2008; Chakraborty et al, 2017) . It is important to acknowledge, however, that even among patients who achieve a prolonged high level of response following initial therapy, many will ultimately relapse (Laubach et al, 2016a; Sonneveld & Broijl, 2016) . With the relapse of MM, other challenges in disease management come into play, such as the heterogeneity of the relapsed population, the emergence of treatment resistance and the need to be increasingly mindful of tolerability profiles (Wildes et al, 2014; Nooka et al, 2015) . The aim of this review is to evaluate the optimal use of novel agents in relapsed MM by collating the latest clinical evidence from this rapidly evolving field. who develop symptomatic relapse, typically a rapidly rising paraprotein level or extramedullary disease (Laubach et al, 2016a) . The European Society for Medical Oncology (ESMO) offers some guidance on the treatment of relapsed and refractory MM, prefacing the very brief discussion of specific drugs with the recommendation that therapy should be chosen on the basis of various disease and patient characteristics . At the time of their publication (2013), these guidelines indicated that the most commonly used regimens were lenalidomide or bortezomib, both in combination with dexamethasone . However, the availability of novel agents has created a much more extensive choice of treatments (Table I ) and has opened up the possibility of triplet regimens in this setting as long as tolerability is not impaired. As a testament to this rapidly evolving field, the ESMO guidelines recommend that, when possible, patients with relapsed MM should be offered the opportunity to participate in a clinical trial .
Established backbone regimens
Backbone regimens are those to which additional treatments are added. Established backbone regimens for the treatment of patients with relapsed or refractory MM consist of either lenalidomide or bortezomib, combined with dexamethasone.
Lenalidomide and dexamethasone
Support for the use of lenalidomide plus dexamethasone (len/dex) comes from the results of two randomised, multicentre, placebo-controlled trials: MM-009 (Weber et al, 2007) and MM-010 (Dimopoulos et al, 2007) . The median time to disease progression with len/dex was 11Á1 months in MM-009 and 11Á3 months in MM-010, compared with 4Á7 months with placebo/dex in both trials (P < 0Á001 in both studies) (Dimopoulos et al, 2007; Weber et al, 2007) . Complete responses (CRs) or partial responses (PRs) were achieved in 61Á0% of len/dex-treated patients in MM-009 and 60Á2% in MM-010; the corresponding rates in the placebo/dex groups were 19Á9% and 24Á0%, respectively (P < 0Á001 in both studies). Both trials recruited patients who had previously received at least one anti-MM treatment and were not resistant to dexamethasone (defined as experiencing disease progression during previous high-dose dexamethasone therapy). The proportion of patients who had received at least two previous therapies was slightly higher in the MM-010 group (approximately 68%) than in the MM-009 group (approximately 62%) (Dimopoulos et al, 2007; Weber et al, 2007) .
Bortezomib and dexamethasone
The efficacy of bortezomib in combination with dexamethasone (bort/dex) has been evaluated in a number of phase 2 and phase 3 trials in patients with relapsed or refractory MM (Jagannath et al, 2006; Mikhael et al, 2009; Dimopoulos et al, 2013) . The impact of adding dexamethasone to bortezomib in patients who had previously experienced a suboptimal response to bortezomib monotherapy was investigated in two open-label phase 2 studies: SUMMIT (Study of Uncontrolled Myeloma Management with proteasome Inhibition Therapy) (Richardson et al, 2003) and CREST (Clinical Response and Efficacy Study of bortezomib in the Treatment of refractory myeloma) (Jagannath et al, 2004 (Jagannath et al, , 2006 . SUM-MIT investigated patients who had received at least two lines of anti-MM therapy and had experienced disease progression during or within 60 days of completion of their most recent therapy, whereas CREST enrolled individuals whose disease had progressed during or after completion of first-line therapy. The addition of dexamethasone to bortezomib resulted in improved responses in 18% of evaluable patients in SUM-MIT and 33% of those in CREST. Overall survival (OS) ranged from 26Á8 to 60Á0 months in the CREST trial, with a 1-year OS of 81-82% (Jagannath et al, 2008 Further support for the efficacy of bort/dex comes from a global phase 3b expanded access programme (Mikhael et al, 2009) . Patients were eligible to take part if they had relapsed or refractory MM after at least two lines of treatment; patients in whom progressive disease had been the best response to prior bortezomib therapy were excluded. All patients received bortezomib for up to eight cycles (median five cycles), with dexamethasone being added to the regimen for patients with progressive disease after two or more cycles or for those with stable disease after four or more cycles. The overall response rate (ORR) was 67%, including 11% CRs and 22% very good PRs. Bortezomib may be administered as an intravenous infusion or as a subcutaneous injection; noninferiority with respect to efficacy has been established between the two administration routes (Moreau et al, 2011; Arnulf et al, 2012) . Subcutaneous injection has, however, been found to be more time efficient and is preferred by patients over intravenous infusion (Barbee et al, 2013) .
In summary, the results of these studies show that the combination of either lenalidomide or bortezomib with dexamethasone offers good response rates and survival benefits in a broad variety of patients with relapsed and/or refractory MM, including heavily pre-treated patients. Hence, they are used as the backbones for current treatment regimens.
Adding a third agent to lenalidomide and dexamethasone
Several trials have evaluated the addition of a third agent to the len/dex backbone. For example, 64% of patients in a phase 2 trial of bortezomib, lenalidomide and dexamethasone achieved PRs or better . This combination is not discussed in detail here because of the lack of phase 3 data. With the emergence of novel therapies, data suggest that carfilzomib, ixazomib, elotuzumab and daratumumab may each be suitable for use in combination with len/dex. The primary efficacy data from the phase 3 trials discussed in this section are summarised in Table II. When interpreting the data, it is important to evaluate the differences in the patient populations enrolled in the trials. While there was little variation across the four studies in terms of median age, some baseline characteristics varied considerably. For example, differences in the eligibility criteria regarding previous lenalidomide treatment may have impacted on the results observed in these trials.
Carfilzomib
The combination of carfilzomib, lenalidomide and dexamethasone (carf/len/dex) was compared with len/dex in a phase 3 trial in patients with relapsed MM (ASPIRE Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone for the Treatment of Patients with Relapsed Multiple Myeloma; ClinicalTrials.gov identifier: NCT01080391) (Stewart et al, 2015) . The primary endpoint was progressionfree survival (PFS). Findings from an interim analysis were published when about a quarter of patients were still receiving treatment, and 431 reports of PFS had been documented (Stewart et al, 2015) . The study had met its primary objective of showing that carf/len/dex improved PFS, with a median PFS of 26Á3 months compared with 17Á6 months for len/dex [hazard ratio (HR) for progression or death, 0Á69; P < 0Á001]. The PFS benefit with carf/len/dex was consistent regardless of age, sex, b 2 -microglobulin level and previous exposure to bortezomib or lenalidomide. The PFS benefit of carf/len/dex was also observed regardless of cytogenetic risk; in patients with standard or high-risk cytogenetics, 10-and 9-month improvements in PFS, respectively, were reported in a preplanned sub-analysis of ASPIRE; this improvement was statistically significant for patients in the standard-risk cytogenetics group (P = 0Á0039) (Avet-Loiseau et al, 2016) .
The median OS endpoint had not been reached in either group at the time of the interim PFS analysis (a total of 510 deaths needed to have been accrued to assess OS; 305 deaths had been reported). ORRs were 87Á1% in the carf/len/dex group and 66Á7% in the len/dex group (P < 0Á001), with a median duration of response of 28Á6 months with carf/len/dex compared with 21Á2 months with len/dex (Stewart et al, 2015) . The rates for patients achieving a CR or better were 31Á8% and 9Á3% with and without carfilzomib, respectively (P < 0Á001) (Stewart et al, 2015) . In a post hoc analysis, the median time to CR or better was 6Á7 months with carf/len/dex and 8Á3 months with len/dex . Cumulative rates of CR of better were higher with carf/len/dex than with len/dex, particularly in the first 15 months of treatment, and by month 30 the respective rates were 31Á9% and 9Á3% . With regard to safety, adverse events (AEs) that occurred in at least 5% more patients treated with carf/len/dex than in those receiving len/dex included hypokalaemia, cough, upper respiratory tract infection, diarrhoea, pyrexia, hypertension, thrombocytopenia, nasopharyngitis and muscle spasms. There was no meaningful difference between groups in the incidence of peripheral neuropathy (17Á1% with carf/len/dex and 17Á0% with len/dex). AEs of grade 3 or higher occurred at similar rates in the carf/len/dex and len/dex groups (83Á7% and 80Á7%, respectively), as did serious AEs (59Á7% and 53Á7%, respectively) (Stewart et al, 2015) . Grade 3 or higher AEs of interest in the carf/len/dex and len/dex study groups, respectively, were dyspnoea (2Á8% and 1Á8%), hypertension (4Á3% and 1Á8%), acute renal failure (3Á3% and 3Á1%), cardiac failure (3Á8% and 1Á8%) and ischaemic heart disease (3Á3% and 2Á1%) (Stewart et al, 2015) . Overall, 14 deaths were reported as being related to treatment (in six carf/len/dex-treated and eight len/dex-treated patients). AEs leading to more than two deaths in either the carf/len/dex or the len/dex group were myocardial infarction (three and one deaths, respectively), cardiac failure (one and three deaths) and sepsis (three and two deaths). An analysis of health-related quality of life (HRQoL) results from ASPIRE revealed that carf/len/dex was associated with significantly greater global 
ELOQUENT-2 (NCT01239797) REL 
health scores on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 module (EORTC QLQ-C30) scale than len/dex alone (P < 0Á001), with a higher proportion of patients achieving at least a five-point improvement at cycle 18 (24Á2% vs 12Á9%; P < 0Á001) .
Elotuzumab
The elotuzumab/len/dex (elo/len/dex) combination was assessed in the phase 3 ELOQUENT-2 study (ClinicalTrials.-gov identifier: NCT01239797) . The co-primary endpoints of this trial were PFS and ORR. At the time of publication, the required number of OS events (427 deaths)
had not yet been accrued, and final results for the co-primary endpoints (PFS and ORR) were reported on the basis of a planned interim analysis of PFS. The 646 patients enrolled in this study had relapsed or refractory MM; approximately onethird of them were resistant to their most recent line of therapy. It is noteworthy that 32% of the patients in each treatment group had the del(17p) variant, which is associated with a poor outcome. PFS was 19Á4 months in the elo/len/dex group and 14Á9 months in the len/dex group, translating to a 30% reduction in the risk of disease progression or death (HR, 0Á70; P < 0Á001). This PFS benefit was consistent across key subgroups, including patients aged 65 years or older, those with resistance to the most recent line of therapy, those with previous exposure to bortezomib or immunomodulatory drugs, and those with previous stem cell transplantation. Approximately one-third of patients had high-risk cytogenetics, and the PFS benefit of elo/len/dex over len/dex alone was also observed in this subgroup . The ORR in the elo/len/dex group was 79%, compared with 66% in the len/dex group (P < 0Á001). Fewer patients in the elo/len/dex group than in the len/dex group had a CR or better (4% vs 7%). Furthermore, it is noteworthy that 33% of elo/ len/dex-treated patients had a very good PR or better, compared with 28% of those in the control group ; the response rates in the elo/len/dex group may have been underestimated owing to the presence of circulating elotuzumab in serum, which can interfere with serum protein immunofixation assays . Serious AEs were reported in 65% and 57% of patients, with grade 3/4 events in 34% and 44% of individuals in the elo/len/dex and len/dex groups, respectively. The most common grade 3/4 haematological AE in the two groups was lymphopenia (in 77% and 49% of patients); the most common grade 3/4 nonhaematological AE was fatigue (8% in each group). Infusion reactions occurred in 10% of patients in the elo/len/dex group (9% grade 1/2, 1% grade 3). The study also recorded data on pain and HRQoL, which were assessed using the Brief Pain Inventory-Short Form, the EORTC QLQ-C30 and the myeloma-specific module (EORTC QLQ-MY20). No significant differences in HRQoL or pain severity scores were identified between the two treatment groups.
Ixazomib
Based on dose-finding data from a phase 1/2 study in 65 previously untreated patients who received ixazomib, lenalidomide and dexamethasone (ixa/len/dex) ) the phase 3 randomised, double-blind, placebo-controlled TOURMALINE-MM1 trial was completed. This trial compared ixa/len/dex with len/dex in 722 patients with relapsed and/or refractory MM (ClinicalTrials.gov identifier: NCT01564537) . At the time of publication, the median OS endpoint had not been reached in either study group. At a median follow-up of 14Á7 months, the primary endpoint of PFS was significantly longer in the ixa/len/dex group than in the len/dex group (20Á6 vs 14Á7 months; HR, 0Á74; P = 0Á01). Subsequently, a non-inferential analysis was conducted at a median follow-up of 23 months, which found that the median PFS was 20 months with ixa/len/dex and 15Á9 months with len/dex. The first analysis showed that the PFS benefit was demonstrated consistently across pre-specified patient subgroups, including individuals with high-risk cytogenetics (19% of all patients). The median PFS was similar for patients with standard-or high-risk cytogenetics who received ixa/len/dex (20Á6 and 21Á4 months, respectively) and was longer than for those who received len/dex (15Á6 and 9Á7 months, respectively) . The ORRs were 78% in the ixa/len/dex group and 72% in the len/dex group (P = 0Á04); the corresponding rates of CR or better were 12% and 7%, respectively (P = 0Á02). The 23-month analysis found that almost all participants experienced AEs (98% in the ixa/len/ dex group and 99% in the len/dex group), with AEs of at least grade 3 being reported in 74% and 69% of patients, respectively. There were 15 deaths (4%) in the ixa/len/dex group and 23 (6%) in the len/dex group. Thrombocytopenia of grade 3 and grade 4 occurred more frequently in the ixa/ len/dex group (12% and 7%, respectively) than in the len/ dex group (5% and 4%, respectively). Gastrointestinal AEs were also more common in patients who received ixa/len/dex than in those who received len/dex alone, but they occurred primarily within the first 3 months after initiation of therapy and were of low grade and manageable with supportive therapy. The incidence of rash was 36% in the ixa/len/dex group and 23% in the len/dex group; the difference between groups was driven primarily by grade 1 and grade 2 events. Peripheral neuropathy occurred in 27% and 22% of patients in the two groups, respectively. The study also recorded HRQoL using patient self-reported instruments, including EORTC QLQ-C30 global health status scores and EORTC QLQ-MY20 side effects scores; results were reported to be similar in the two treatment groups at the 23-month analysis.
Daratumumab
A phase 3 trial comparing the combination of daratumumab, lenalidomide and dexamethasone (dara/len/dex) with len/dex alone in patients with relapsed or refractory MM (MMY3003, POLLUX; ClinicalTrials.gov identifier: NCT02076009) is ongoing, with an estimated primary completion date of May 2017. However, after a median followup of 13Á5 months, data have been presented from 569 enrolled patients [https://clinicaltrials.gov/ct2/show/ NCT02076009?term=NCT02076009&rank=1 (Accessed October 2016); Dimopoulos et al, 2016b] . At this point, the dara/ len/dex combination was associated with a 63% reduction in the risk of disease progression or death and a 66% reduction in the time to disease progression compared with len/dex (P < 0Á001 for both). The addition of daratumumab to len/ dex also significantly increased the ORR (93% vs 76%; P < 0Á001) and the rate of CR or better (43% vs 19%; P < 0Á001) compared with len/dex alone. The PFS benefits were observed across all pre-specified subgroups, including patients with different numbers of previous lines of therapy and those with previous exposure to lenalidomide (Dimopoulos et al, 2016b) . For patients who had received at least one previous line of therapy and had high-risk cytogenetics, PFS was significantly longer in the dara/len/dex group than in the len/dex group (not reached vs 8Á3 months; P = 0Á0019) (Usmani et al, 2016a) . The most common grade 3/4 treatment-emergent AEs were neutropenia (in 52% and 37% of patients in the dara/len/dex and len/dex arms, respectively), thrombocytopenia (13% and 14%) and anaemia (12% and 20%). Infusion-related reactions associated with dara/len/dex occurred in 48% of patients; 95% were of grade 1/2 and 92% occurred during the first infusion (Dimopoulos et al, 2016b) .
Cyclophosphamide
A phase 1/2 dose-escalation study of len/dex combined with cyclophosphamide found an ORR of 81% and a projected 2-year PFS of 56% (Schey et al, 2010) . Furthermore, the 30-month OS was estimated to be 80% (Schey et al, 2010) . Despite these early promising results, no phase 3 study of this combination has been completed.
Adding a third agent to bortezomib and dexamethasone
The benefits of combining bortezomib and dexamethasone (bort/dex) in patients with relapsed MM have been demonstrated in the clinical trial setting (Richardson et al, 2003; Jagannath et al, 2004) . Addition of a third agent to bort/dex appears to have the potential to improve the response further. Primary efficacy data from the phase 3 trials discussed in this section are summarised in Table II . As with the trials using a len/dex backbone, the patient populations enrolled in the bort/dex backbone studies varied in some respects. In PANORAMA-1 (panobinostat or placebo with bortezomib and dexamethasone in patients with relapsed multiple myeloma: panobinostat, bortezomib and dexamethasone vs bort/ dex; ClinicalTrials.gov identifier: NCT01023308), 43% of patients had previously received bortezomib, whereas in CASTOR (daratumumab, bortezomib and dexamethasone vs bort/dex; ClinicalTrials.gov identifier: NCT02136134), 68% of patients had previously received a proteasome inhibitor Palumbo et al, 2016) . In addition, the study design differed, with a maximum treatment duration of 12 cycles in PANORAMA-1 and a maximum of eight cycles of bortezomib in CASTOR (daratumumab was given until unacceptable toxicity, disease progression or withdrawal of consent occurred) Palumbo et al, 2016) .
Panobinostat
The pivotal phase 3 trial in the development of panobinostat was PANORAMA-1, a multicentre, randomised, placebo-controlled, double-blind, phase 3 trial of 768 patients with relapsed and/or refractory MM who had received one to three previous treatment regimens ( San-Miguel et al, 2014) . Patients with bortezomib-refractory MM were excluded from entering this study. With a median follow-up of 6Á5 months in individuals receiving panobinostat with bortezomib and dexamethasone (pan/bort/dex) and 5Á6 months in those receiving bort/dex alone, the median PFS was significantly longer in the former group (12Á0 months vs 8Á1 months; HR, 0Á63; P < 0Á001) . The PFS benefit in the pan/bort/dex group compared with the bort/dex alone group was more pronounced in patients with high-risk cytogenetics (HR, 0Á47) than in those at standard risk (HR, 0Á88), although this difference was not statistically significant . There was no significant difference in ORR between the pan/bort/dex and bort/dex groups (60Á7% vs 54Á6%, respectively; P = 0Á09). CR rates were 11% and 6%, respectively, and a significantly higher proportion of patients in the pan/bort/dex group achieved a CR or near CR than in the bort/dex group (27Á6% vs 15Á7%; P < 0Á001). The median OS was not significantly different between the two treatment arms: 40Á3 months in the pan/bort/dex group and 35Á8 months in the bort/dex group . The most common grade 3/4 AEs in the pan/bort/dex group were diarrhoea (25Á5%) and asthenia/fatigue (23Á9%), which occurred in 8Á0% and 11Á9% of patients in the bort/ dex group, respectively . Grade 3/4 thrombocytopenia, lymphopenia and neutropenia occurred in 67Á4%, 53Á2% and 34Á5% of patients in the pan/bort/dex group, respectively, compared with 31Á4%, 39Á8% and 11Á4% of patients in the bort/dex group. In the pan/bort/dex group, 8% of patients died during treatment compared with 5% in the bort/dex group .
Elotuzumab
No phase 3 trials have been initiated with elotuzumab, bortezomib and dexamethasone (elo/bort/dex) in patients with relapsed MM. However, this combination is being studied in patients with relapsed and/or refractory MM in an open-label phase 2 trial (ClinicalTrials.gov identifier: NCT01478048) (Jakubowiak et al, 2016a,b) . Patients were randomised to receive either elo/bort/dex or bort/dex alone. It is notable that all five of the patients identified as being at high cytogenetic risk were in the bort/dex group (comprising 7% of individuals in that group). The median PFS was 9Á7 months with elo/bort/dex compared with 6Á9 months with bort/dex, translating to a 28% reduction in the risk of disease progression or death. This PFS benefit was consistent across all key predefined subgroups. The ORRs were similar in the two treatment groups (66% and 63%, respectively), and a CR or better occurred in 4% of patients in each group. The most common grade 3 or higher AEs were infections (21% in the elo/bort/dex group and 13% in the bort/dex group) and thrombocytopenia (9% and 17%, respectively). Serious AEs occurred in 51% of the elo/bort/dex group and 41% of those who received bort/dex only. To date, deaths have occurred in similar numbers of patients in the two groups (elo/bort/dex group, 28; bort/dex group, 32). The rate of infusion reactions in the elo/bort/dex therapy group was low (5%), and all of these were of grade 1/2.
Daratumumab
The triplet combination of daratumumab, bortezomib and dexamethasone (dara/bort/dex) is being evaluated in a phase 3 trial of patients with relapsed and/or refractory MM (CAS-TOR) . Patients in this trial were allowed to have prior exposure to bortezomib but not to be refractory to bortezomib treatment. Interim data have been published demonstrating that after a median follow-up of 7Á4 months, the median PFS endpoint had not been reached in the dara/bort/dex group and was 7Á2 months in the bort/ dex group, giving a 61% reduction in the risk of disease progression or death (P < 0Á001) . A subanalysis of data from CASTOR in patients with high-risk cytogenetics who had received at least one previous treatment found that PFS was significantly longer in individuals who received dara/bort/dex than in those who received bort/ dex (HR, 0Á46; P = 0Á0367) . For patients with high-risk cytogenetics, the estimated 12-month PFS was 63Á2% for the dara/bort/dex group and 26Á7% for the bort/ dex group . The ORR was higher in the dara/bort/dex group than in the bort/dex group (82Á9% vs 63Á2%; P < 0Á001), as were the rates of CR or better (19Á2% vs 9Á0%; P = 0Á001) . The most common grade 3/4 AE was thrombocytopenia (45Á3% and 32Á9% in the dara/bort/dex and bort/dex groups, respectively). In the triplet therapy group, 45Á3% of patients had infusionrelated reactions associated with daratumumab treatment; these were mostly of grade 1/2 (in 91Á4% of patients) and occurred during the first infusion (98Á2%).
Pomalidomide
A phase 3 study investigating the combination of pomalidomide, bortezomib and dexamethasone compared with bort/ dex in patients with relapsed or refractory MM is under way, 
Cyclophosphamide
A phase 2 trial investigating the combination of bortezomib, intermediate-dose dexamethasone and continuous low-dose cyclophosphamide found an ORR of 90% (at least a minor response) (Kropff et al, 2007) . The median OS was 22 months, and the most common grade 3/4 AEs were thrombocytopenia, leucopenia, infections, fatigue and herpes zoster; 21% of patients had grade 3 or 4 peripheral neuropathy (Kropff et al, 2007) . In another study, patients received this combination as an induction regimen, followed by 1 year of maintenance therapy (de Waal et al, 2015) . An ORR of 71% was reported, and the median PFS and OS were 18Á4 and 28Á1 months, respectively (de Waal et al, 2015) . The most common AEs were related to myelosuppression and 15% of patients developed grade 3 or 4 peripheral neuropathy (de Waal et al, 2015) .
Novel backbone regimens for advanced MM

Carfilzomib
Based on phase 1b/2 trial data showing the promising activity and tolerability of carfilzomib in combination with dexamethasone (carf/dex) in patients with relapsed and/or refractory MM (Papadopoulos et al, 2015) , the ENDEAVOR (randomized, open label, phase 3 study of carfilzomib plus dexamethasone vs bortezomib plus dexamethasone in patients with relapsed multiple myeloma) trial (ClinicalTrials.gov identifier: NCT01568866) was initiated to compare carf/dex with bort/dex (Dimopoulos et al, 2016c) . Previous treatment with carfilzomib or bortezomib was permitted if patients had achieved at least a PR before relapse or disease progression, had not discontinued therapy because of AEs and had at least a 6-month treatment-free interval following treatment with a proteasome inhibitor. The enrolled patients generally had similar characteristics to those in the PANOR-AMA-1 and CASTOR studies, notably with respect to the proportion of patients who had received previous bortezomib treatment (54% in ENDEAVOR vs 43% and 66% in PANORAMA-1 and CASTOR, respectively) (San-Miguel et al, 2014; Dimopoulos et al, 2016c; Palumbo et al, 2016) . Patients received treatment until their disease progressed. A baseline characteristic of note was the proportion of patients at high cytogenetic risk (21% and 24% in the carf/dex and bort/dex groups, respectively). An interim analysis (median follow-up of 11Á9 months) of the 929 enrolled patients showed that the median PFS was 18Á7 months with carf/dex compared with 9Á4 months with bort/dex, translating to a 47% reduction in the risk of disease progression or death (P < 0Á0001). The PFS benefit was seen in all predefined exploratory subgroups, including patients with or without previous bortezomib treatment (Dimopoulos et al, 2016c) . The ORR was significantly higher with carf/dex than with bort/dex (77% vs 63%, respectively; P < 0Á001), as was the rate of patients achieving a CR or better (13% vs 6%; P = 0Á001). Grade 3/4 thrombocytopenia occurred in 8Á4% of patients in the carf/dex group and 9Á4% in the bort/dex group (Dimopoulos et al, 2016c) . The most common grade 3/4 non-haematological AEs were fatigue (in 5Á4% and 7Á0% of patients in the carf/dex and bort/dex groups, respectively) and hypertension (8Á9% and 2Á6%); grade 3/4 peripheral neuropathy occurred in 1Á3% and 5Á3% of patients in the carf/dex and bort/dex groups, respectively. Grade 3-5 AEs of interest included pneumonia (6Á9% and 7Á9% in the carf/dex and bort/dex groups, respectively), acute renal failure (4Á1% and 2Á6%), cardiac failure (4Á8% and 2Á6%), ischaemic heart disease (1Á7% and 1Á5%) and pulmonary hypertension (0Á6% and 0Á2%) (Dimopoulos et al, 2016c) . Serious AEs were reported in 48% of patients receiving carf/dex and in 36% of those receiving bort/dex, and on-study death due to AEs occurred in 4% and in 3% of the patients, respectively (Dimopoulos et al, 2016c) .
The superior efficacy of carf/dex over bort/dex combined with its acceptable safety profile indicates that carf/dex has the potential to become the standard of care for doublet regimens in this patient population.
Pomalidomide
This agent has emerged as a good backbone treatment candidate for third-or later-line therapy in patients with relapsed MM. It is frequently used in this setting in combination with low-dose dexamethasone; data from a randomised phase 3 trial revealed that median PFS was significantly longer when pomalidomide was combined with low-dose dexamethasone than with high-dose dexamethasone (4Á0 months vs 1Á9 months; P < 0Á0001) . The potential for triplet therapy with pomalidomide is under investigation. For example, a phase 2 study (ClinicalTrials.-gov identifier: NCT01432600) of 70 patients with lenalidomide-refractory MM has compared the cyclophosphamide, pomalidomide and dexamethasone triplet combination with the pomalidomide and dexamethasone doublet . The ORRs in these two treatment groups were 64Á7% and 38Á9%, respectively (P = 0Á035), and the PFS periods were 9Á5 and 4Á4 months (P = 0Á106). There was no significant impact on toxicity when cyclophosphamide was added into the regimen.
Case study data have demonstrated the potential benefits of individualising treatment for advanced MM using pomalidomide and dexamethasone as a backbone: a regimen incorporating bortezomib, cyclophosphamide, pomalidomide and dexamethasone resulted in well-tolerated partial remission in a heavily pre-treated patient (Danhof et al, 2015) . In addition, a phase 1 study of carfilzomib, pomalidomide and dexamethasone showed promising response rates and good tolerability (Shah et al, 2015) .
Considerations when making treatment decisions in clinical practice
The increasing number of new therapies under evaluation raises the question of how best to choose the most appropriate regimen. Examination of the HRs obtained in individual studies may improve comparisons between trials. Nonetheless, care must be taken when making cross-trial comparisons, owing to differences in patient characteristics and trial designs. As shown in Table II , trials of regimens containing elotuzumab , ixazomib , carfilzomib (Stewart et al, 2015; San-Miguel et al, 2016) and panobinostat have yielded HRs for PFS of between 0Á53 and 0Á74. By contrast, the HRs for PFS obtained in trials of daratumumab-containing regimens were lower (0Á37-0Á39) (Dimopoulos et al, 2016b; Palumbo et al, 2016) . Importantly, most of these trials evaluated the addition of a new therapy to an established backbone regimen.
A further consideration relevant to the choice of therapy is that the endpoints employed in clinical trials of treatments for patients with relapsed MM may not reflect those that are most relevant in clinical practice. The available data generally focus on PFS and -as data become mature -OS [the latter remains a critical endpoint, particularly in view of the poor survival (typically less than 1 year) of patients with refractory disease]. Nevertheless, it is also important to consider the increasing relevance of tolerability and HRQoL profiles as patients survive for longer periods of time with their disease. A further endpoint that may be clinically relevant is the presence of minimal residual disease (MRD), which is becoming more popular as a means of assessing the depth of response to maintenance therapy in MM (Mewawalla & Chilkulwar, 2017) . Several studies have shown that the absence of MRD is associated with increased PFS and OS (Paiva et al, 2008; Rawstron et al, 2013; Martinez-Lopez et al, 2014) , and this endpoint has been used in a number of recent clinical trials in patients with relapsed or refractory MM, including the POLLUX and CASTOR studies of daratumumab (Dimopoulos et al, 2016b; Palumbo et al, 2016) .
The population of patients with relapsed MM is heterogeneous, not only in terms of disease characteristics but also in terms of treatment history. The inclusion criteria of clinical trials are often narrow and exclude patients with non-secretory or oligosecretory disease. Although such cases are relatively uncommon (1-5% of MM cases) (Khurana et al, 2016) , the lack of clinical trial data for this population means that it can be challenging for physicians to optimise treatment for these individuals. Furthermore, patients with severe renal impairment are also often excluded from clinical trials.
Renal impairment is a common complication in individuals with MM (it is present in approximately 20% of patients) and is caused by the underlying biology of the disease . Anti-myeloma treatment can improve renal impairment; however, care must be taken because of the potential nephrotoxicity associated with certain agents, for example, ixazomib (http://www.ema.europa.e u/docs/en_GB/document_library/EPAR_-_Product_Informa tion/human/003844/WC500217620.pdf, Accessed 21 February 2016) and lenalidomide (http://www.ema.europa.eu/docs/en_ GB/document_library/EPAR_-_Product_Information/human/ 000717/WC500056018.pdf, accessed 22 July 2016); dose adjustments may be necessary (Table III) . In addition to renal issues, hepatic impairment is an important consideration when choosing a treatment regimen. However, most agents have not been investigated in patients with severe renal or severe hepatic impairment, so information on dose adjustments and when to withhold dosing is scarce. Table III provides an overview of dose modifications, and requirements before initiating therapy, that are recommended in the summary of product characteristics for approved agents. An individualised approach to treatment is particularly relevant once MM relapses (Sonneveld & Broijl, 2016) ; thus, agents demonstrating influence in a particular patient group, or indeed over a specific clinical feature, may be useful tools for managing the later stages of the disease (Anderson et al, 2008) . For example, bone manifestations in MM are common, particularly in individuals with advanced disease, and can be painful and substantially impair patients' lives. Up to 80% of patients will experience a fracture during the course of their disease, and most of these fractures are pathological (Melton et al, 2005) ; therefore, bone disease endpoints are important, but they are not currently examined in clinical trials. Although initial treatment strategies depend largely on a patient's ability to tolerate intensive regimens, an agent's tolerability profile may exert more influence over treatment choice following relapse because patients are ageing, and the medication burden is probably increasing (Wildes et al, 2014; Naymagon & Abdul-Hay, 2016) .
With the recent (February 2017) approval by the Committee for Medicinal Products for Human Use (CHMP) of daratumumab in combination with len/dex or bort/dex for the treatment of adults with MM who have received at least one previous therapy (European Medicines Agency 2016), two monoclonal antibodies are now available for this indication. However, the two products differ markedly in pharmacological and clinical properties. Daratumumab is a human monoclonal antibody that binds to CD38, a cell-surface protein expressed in malignant plasma cells, and was originally approved as monotherapy for patients with relapsed or refractory MM (http://www.ema.europa.eu/docs/en_GB/docu ment_library/EPAR_-_Product_Information/human/004077/ WC500207296.pdf, Accessed 22 July 2016). It is given by intravenous infusion at a dose of 16 mg/kg; doses are given weekly in weeks 1-8, fortnightly in weeks 9-24 and every /l, febrile neutropenia, platelet count <10 9 10 9 /l, CrCl <15 ml/min (or ≤50% of baseline) and grade 3/4 non-haematological toxicity (includes cardiac toxicity and dyspnoea). Treatment may be restarted at a reduced dose once symptoms of toxicity have resolved Treatment must be withheld or dose reduced in patients with elevated serum transaminases
Daratumumab (JanssenCilag**)
Pre-infusion medication † Post-infusion medication ‡
The infusion rate may be increased if daratumumab is well tolerated In the event of a grade 1/2 infusion-related reaction, treatment must be stopped but may be resumed at a lower infusion rate once the patient has stabilised Treatment must be withheld in the event of a grade 3 infusion-related reaction
Pre-infusion medication §
The infusion must be stopped in the event of a grade 1/2 infusionrelated reaction, but may be resumed at a decreased rate once the patient has stabilised Treatment must be interrupted for grade ≥2 infusion-related reactions, and may be permanently discontinued for grade ≥3 infusion reactions Ixazomib (Takeda Pharma A/S § §) ANC ≥1 9 10 9 /l Platelet count ≥75 9 10 9 /l Non-haematological toxicities should be corrected to baseline or to ≤ grade 1 Reduced dose (3 mg) recommended for patients with moderate or severe hepatic impairment* Reduced dose (3 mg) recommended for patients with severe renal impairment (CrCl <30 ml/min) or ESRD requiring dialysis Dose reductions may be required for patients with PN, thrombocytopenia and neutropenia Lenalidomide (Celgene Europe Ltd ¶ ¶) ANC ≥1 9 10 9 /l Platelet count ≥75 9 10 9 /l Dose adjustments are required to manage grade 3/4 PN or thrombocytopenia, other grade 3/4 toxicity related to lenalidomide and grade 2/3 rash Reduced dosing for patients with moderate renal impairment (10 mg/day), severe renal impairment (7Á5 mg/day or 15 mg every other day) or ESRD (5 mg/day) ¶ Panobinostat (Novartiskk) ANC ≥1 9 10 9 /l Platelet count ≥100 9 10 9 /l ECG should be recorded (QTcF should be <480 ms) Blood electrolytes and thyroid and liver function should be monitored The dose should be withheld for grade 3/4 platelet counts or neutropenia, or grade 2/3 diarrhoea, and may be resumed at the same dose or at a reduced dose once symptoms resolve A reduced starting dose is required for patients with mild or moderate hepatic impairment* and can be up-titrated if well tolerated Contraindicated in patients with severe hepatic impairment Patients aged ≥65 years should be monitored for signs and symptoms of thrombocytopenia and gastrointestinal toxicity A reduced starting dose may be considered in patients aged >75 years 4 weeks thereafter (http://www.ema.europa.eu/docs/en_GB/d ocument_library/EPAR_-_Product_Information/human/ 004077/WC500207296.pdf, Accessed 22 July 2016). The most common AEs are infusion rate reactions, which occurred in 48% of patients in pivotal clinical trials despite pre-treatment with antihistamines, antipyretics and corticosteroids. Most reactions (95%) occurred at the first injection (http://www.e ma.europa.eu/docs/en_GB/document_library/EPAR_-_Produc t_Information/human/004077/WC500207296.pdf, Accessed 22 July 2016).
Elotuzumab is a humanised monoclonal antibody binding to signalling lymphocytic activation molecule family member 7 (SLAMF7), a cell-surface glycoprotein that is highly expressed in MM cells (http://www.ema.europa.eu/docs/en_ GB/document_library/EPAR_-_Product_Information/human/ 003967/WC500206673.pdf, Accessed 22 July 2016). Pretreatment with antihistamines is required to reduce the likelihood of an infusion-related reaction. Elotuzumab is given by intravenous infusion at a dose of 10 mg/kg on days 1, 8, 15 and 22 of the first two cycles, and on days 1 and 15 of each subsequent cycle (http://www.ema.europa.eu/docs/en_GB/d ocument_library/EPAR_-_Product_Information/human/ 003967/WC500206673.pdf, Accessed 22 July 2016). The incidence of infusion site reactions is markedly lower than that seen with daratumumab; such reactions occurred in approximately 10% of pre-treated patients and in more than 50% of individuals who did not receive pre-treatment. All such reactions were mild or moderate in severity, and 70% of them occurred with the first treatment (http://www.ema.europa.e u/docs/en_GB/document_library/EPAR_-_Product_Informa tion/human/003967/WC500206673.pdf, Accessed 22 July 2016). As treatment regimens begin to incorporate more agents, the dosing complexity can potentially become overwhelming, and the convenience and timing of dose administration will have a considerable impact on a patient's ability to adhere to prescribed schedules. The convenience of different treatment options is dependent on factors, such as the route of administration (oral vs intravenous) and the requirement for hospital visits, which can be a burden for both patients and caregivers. Alternative administration routes and schedules are being explored for some agents, and the first data on subcutaneous daratumumab were presented in 2016 . The AE profiles, pharmacokinetic profiles and initial response rates were found to be similar to those of intravenous daratumumab; the shorter infusion time may be beneficial in clinical practice, but further research is required . The randomised, open-label, phase 3 ARROW study is comparing once-vs twice-weekly carfilzomib (in combination with dexamethasone) dosing (NCT02412878).
In order to provide a comprehensive source of data on which physicians and their patients can base treatment decisions, it will be important for future studies evaluating combinations of these novel agents to incorporate patientreported outcome measures of symptoms and HRQoL. Increasing treatment burdens also carry cost implications and, as more novel agents emerge, cost-effectiveness analyses -such as a recent analysis of carf/len/dex vs len/dex from the United States of America (Jakubowiak et al, 2016c) -will be crucial for ensuring the practicability of adopting triplet therapy regimens. A proposal that relapsed MM could essentially be managed as a chronic illness, with continuous therapy from relapse to progression, will be dependent on the availability of long-term data on the efficacy and tolerability of such an approach (Sonneveld & Broijl, 2016) .
The clinical data presented here offer some potential for the comparison of triplet regimens, although no head-tohead comparisons are available in the relapsed and/or refractory setting. As indicated by the ESMO guidance, treatment choices at this stage of MM need to take account of various disease and patient characteristics . As well as drawing on treatment-specific data, therefore, an individualised approach will consider disease-and patient-related factors, such as age, frailty and cytogenetic risk (Avet-Loiseau et al, 2010; Dimopoulos et al, 2010; Chang et al, 2011; Jakubowiak et al, 2013; Stewart et al, 2015) and personal experience of previous therapies (Kropff et al, 2007; Pineda-Roman et al, 2008; Sonneveld et al, 2008; Wang et al, 2008; Vogl et al, 2009; Dimopoulos et al, 2010; Sonneveld & Broijl, 2016) . Ultimately, as MM progresses, the management approach may become increasingly personalised, a situation that is made possible by the emergence of this new wave of treatment options. Such an approach is also likely to be facilitated by the use of biomarkers, such as gene expression profiling and proteomics, to identify, for example, patients who may be resistant to therapy or individuals who may respond well to certain treatments (Johnson et al, 2011) . A recent study has identified proteins involved in protection from oxidative stress as potential biomarkers of bortezomib resistance (Dytfeld et al, 2016) . In addition, numerous new agents and combinations are under clinical development (Table IV) . It may therefore be anticipated that the treatment landscape in relapsed MM will expand further as new options become available.
Conclusions
Data from clinical trials indicate that significant PFS benefits are to be gained by adding a novel agent to a backbone of len/dex treatment in patients with relapsed MM; phase 3 data are available to support this strategy for carfilzomib, elotuzumab, ixazomib and daratumumab. As yet, the addition of a third agent to a bort/dex backbone has been less well studied, although phase 3 data currently support the addition of panobinostat or daratumumab. New backbones, such as carf/dex or pom/dex, may further expand the choice of treatment regimens. Given the needs of patients at this stage of disease, however, it will be important to generate patient-reported outcome data in order to gauge the potential effects of these new regimens on parameters such as HRQoL and symptom experience.
